|Bid||281.00 x 2200|
|Ask||283.44 x 800|
|Day's Range||272.36 - 281.50|
|52 Week Range||177.93 - 398.88|
|Beta (3Y Monthly)||2.71|
|PE Ratio (TTM)||57.21|
|Earnings Date||Apr 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||295.50|
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A few years ago I was sitting in the dentist chair for my six-month examination and teeth cleaning. As I stared at the ceiling, I couldn't help notice the name Belmont on the arm of the bright light burning a hole in my retina. I couldn't help myself, asking the dentist if she'd ever invested in a dental-related company? She said she hadn't. "Not even Henry Schein (NASDAQ:HSIC)?", I asked. Nope. That was the end of the investment discussion. Recently, I saw an article that said dental startups such as Candid and Smile Direct Club, which provides systems for mild-to-moderate teeth straightening -- saving you a bundle in the process -- have investors lining up to invest in the private companies. InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, that brought me back to that day in the dentist's chair, when I wondered about stocks to buy that will make you smile. * 10 Stocks That Are Screaming Buys Right Now Here are seven names I've identified that will put money in your pockets. Henry Schein (HSIC)Source: Shutterstock If you're a dentist, you've likely got Henry Schein on speed dial. It distributes more than 120,000 branded products and another 180,000 private label products to dentists and medical practitioners. It is the No. 1 global dental distributor and the No. 2 physician and alternate care distributor in the U.S. In fact, 90% of U.S. dental practices are active Schein customers. So, the next time you go to the dentist, be sure to ask how much stuff they buy from the company. It's probably a lot. Things seem to be going smoothly for the Melville, New York, company, yet HSIC is currently trading within 13% of its 52-week low and up less than 5% year-to-date through April 10, one-third the performance of the S&P 500.On three occasions over the past five years, it traded below $55. Within five dollars of doing so a fourth time, HSIC is entering value territory. Fear not. In 2018, Henry Schein's revenues grew by 5.9% year-over-year to $13.2 billion, while its non-GAAP earnings rose 11.4% to $635.3 million, its highest level of sales and profits in its history. Now, exclusively a company dealing with humans after spinning off its animal health business, Henry Schein is ready to take dental to the next level. 3D Systems (DDD)Source: Image via 3D Systems3D Systems (NYSE:DDD) is a 3D printer. Over the past five years as the demand for 3D printing has slowed, so too has the company's revenue and earnings growth. As a result, DDD shares have lost 80% of their value. In 2019, DDD is up more than 7% year-to-date through April 10. However, it lost a great deal of its momentum in March, giving back 23% of its gains on the year. The company's dental segment continues to take a bite out of the competition. It produces dentures, crowns and surgical guides. "There are billions of opportunities here, since virtually anybody could benefit from 3-D printed dental solutions," said CEO Vyomesh Joshi recently. On a non-GAAP basis, 3D Systems went from a $1.7 million loss in 2017 to a $16.5 million gain in 2018 on the strength of a 6% increase in revenue to $688 million. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Trading at 1.8 times revenue, less than half its five-year average price-to-sales ratio, DDD provides investors with an excellent value proposition. Align Technology (ALGN)Source: Shutterstock As dentists go, mine wasn't too pushy about trying the latest and greatest dental product or service, but she sure liked to talk up Invisalign, the $8,000 clear aligner that straightens your teeth. Made by Align Technology (NASDAQ:ALGN), I never took the bait. Now, having moved from Toronto to Halifax over a year ago, and still without a new dentist, I suspect I'll soon be getting the Invisalign sales pitch a second time. Perhaps, startups like Candid are taking a bite out of Align's market share. Given the $4,000 price over 24 months for its teeth alignment product, a good $3,000-$4,000 cheaper than the competition, it's easy to see why. However, I don't think investors should give up on ALGN just yet. As I look at the company's results for 2018, I see a lot of positives.On the top line, revenues grew 34% to $2 billion, a company record, on a 32% increase in Invisalign volume. On the bottom line, net profits were $400.2 million in 2018, 73% higher than a year ago. Forget for a moment that Invisalign didn't exist. Its iTero scanners experienced 68% growth in 2018; iTero's revenues now account for 14% of Align's overall revenue, up 290 basis points from 2017. Trading well off its all-time high of $398.88, investors buying in today, should have significant upside in the months ahead. Dentsply Sirona (XRAY)Source: Shutterstock I first became familiar with Dentsply Sirona (NASDAQ:XRAY) way back in March 2013, more than two years before Dentsply would pay $5.5 billion for Sirona Dental Systems, a company I liked because of its diversified revenue streams. "Sirona's revenue diversification is what makes it such a good company. It generates business from four operating segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments," I wrote March 20, 2013. "Its CAD/CAM and Imaging Systems accounted for 70% of its overall revenue in the first quarter ended December 2012."If you took my advice and bought 100 shares of Sirona at the Q2 2013 high of $73.98, today you'd have $9,158, a 24% return. But over three years, it's seen a mediocre 5% return. So, do I still think XRAY is worth holding for the long haul?I do. Here's why.Like most acquisitions, the tie-up didn't go nearly as smoothly as hoped. As a result, the company was forced to implement a turnaround plan that will simplify its business. Where have I heard that before?Anyway, when you bring together two reasonably large businesses, you often lose focus on parts of it and those units suffer. So, it's exiting these businesses and cutting staffing by as much as 8%. By fiscal 2020, analysts expect it to earn $2.64 a share, its best earnings performance since 2016. * The 7 Best Long-Term Stocks for 2019 And Beyond It has had a good run in 2019, up 36% year-to-date. I'd be patient and try to buy on weakness in the mid-$40s. Patterson Companies (PDCO)Source: Shutterstock A little over two years ago, Globe and Mail business reporter Scott Barlow highlighted 12 healthcare stocks that had stable cash flow. He argued that businesses such as Patterson Companies (NASDAQ:PDCO), a distributor of dental and animal health products, would make you rich over the long haul because of this critical attribute. Since the article, PDCO stock has lost approximately half its value. Ouch.However, in the nine months ended Jan. 27, 2019, Patterson's operating cash flow increased 91% to $76.3 million. After subtracting $33.9 million in capital expenditures, it generated free cash flow of $42.4 million or 77% of its net income. On the top line, revenues in the first three quarters of fiscal 2019 barely budged, up 1.8% to $4.14 billion. On the bottom line GAAP basis, its net income fell 69% to $55.2 million. On an adjusted basis, earnings fell 25% to $95.9 million. While this article is about dental businesses, Patterson's animal health business (58% of revenue) continues to provide PDCO with diversified revenue streams that will protect it when the economy turns south because a lot of pet owners won't scrimp on their companion animal's wellbeing. Yielding 4.8% at the moment, it has plenty of free cash flow to keep paying its juicy dividend. If you're an income investor, PDCO is an excellent stock to own before the company's restructuring takes hold. Get paid to wait. Procter & Gamble (PG)Source: Mike Mozart via Flickr (Modified)My old dentist's dental technician recommended that I buy an Oral-B electric toothbrush because it does a better job of brushing your teeth without overdoing it, thus hurting your gums. She was right. Originally invented in 1950 by California periodontist Dr. Robert Hutson, he sold the company to Cooper Laboratories, who in turn sold it to Gillette in 1984 for $188.5 million. The rest, as they say, is history. On April 9, Oral-B's owner, Procter & Gamble (NYSE:PG), raised its quarterly dividend by 4% to 74.59 cents a share, an annualized rate of $2.98, yielding 2.8% despite a 37% gain over the past 52 weeks. This is P&G's 63rd consecutive year increasing its dividend. Oral-B and the rest of its oral care brands generated 9% of P&Gs revenue in the second quarter. Part of the healthcare segment, sales and earnings were both up slightly in the first quarter, delivering solid if not spectacular results. * The 10 Fastest-Growing Stocks to Invest In Right Now Consider Oral-B the company's slow-growth business. Overall, however, Procter & Gamble is doing just fine. Church & Dwight (CHD) Source: slgckgc via Flickr (Modified)Church & Dwight (NYSE:CHD) is a smaller version of P&G. But make no mistake, it competes with the best of them. As far as dental care goes, it has Arm & Hammer, AIM, Close-Up and Pepsodent toothpaste. Other brands include Orajel and Waterpik. The company has become adept at making smaller acquisitions and then growing those businesses over time. Most recently, it announced it had acquired two hair removal brands, Flawless and Finishing Touch, for $475 million and a further $425 million in potential earnouts. The two brands add $180 million in annual revenue and $55 million in EBITDA.The owners of Flawless would have been wise to ask for stock instead of cash because over the past decade, CHD stock has delivered an annualized total return of 19.4%, almost double P&G.As stocks go, CHD is a perfect 10. I urge you to check it out. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post 7 Dental Stocks to Buy That Will Make You Smile appeared first on InvestorPlace.
Align Technology (ALGN) closed at $293.08 in the latest trading session, marking a +1.18% move from the prior day.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders...
Align Technology, Inc. (ALGN), makers of the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners, announced today that it has completed the purchase of the office building where it currently resides, 3030 Slater Road, Morrisville, NC for sum of $58,100,000. Headquartered in San Jose, California, Align first opened a Raleigh office in July 2015 with just 14 employees. For more information about career opportunities at Align and to learn more about how we have helped create over 6.4 million smiles globally with Invisalign clear aligners, please visit www.aligntech.com/careers or follow the #LifeatAlign recruitment campaign via Align's LinkedIn page.
SAN JOSE, Calif., April 01, 2019 -- Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report first quarter 2019 financial results on Wednesday, April.
If you are stuck for investing inspiration after a breakneck first quarter, Goldman Sachs has some valuable tips. The firm has just released a report advising investors to focus on growth stocks with rapidly growing revenues. These are the kinds of companies that should outperform as costs rise over the coming year, Goldman analysts say."Mounting pressures from wage inflation and other input costs will pressure margins, making further expansion from currently all-time high margins unlikely," writes David Kostin, Goldman Sachs' head U.S. equity strategist. "As a result, growth in (earnings per share) will be driven entirely by top-line sales."That's already playing out so far this year. Goldman Sachs recently calculated that stocks it considers "high revenue" have outperformed the Standard & Poor's 500-stock index by 400 basis points already since the start of 2019.Here are seven growth stocks to buy, according to Goldman's expectations for high revenue expansion across the rest of 2019. SEE ALSO: The 25 Best Blue-Chip Stocks to Buy Now (According to Hedge Funds)
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Align Technology, Inc. (ALGN) and Straumann Group (SIX:STMN) announced today that they have reached an agreement to settle all currently outstanding patent disputes in the U.S., the U.K. and Brazil, including those involving ClearCorrect, a subsidiary of Straumann Group. Under the terms of the settlement, Straumann will pay Align $35 million.
Rising labor costs are exerting downward pressure on corporate profit margins, but these stocks are well-positioned to meet the challenge.
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Align Technology, Inc. (NASDAQ:ALGN) is a stock with outstanding fundamentalRead More...
Align Technology, Inc. (ALGN), today announced the opening of the Align University Training Institute in Shanghai, China. This is Align’s second training facility in China. The state-of-the-art facility represents the company’s commitment to clinical education and support for doctors in China.
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.